Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 12, Issue 3, 2012, Pages 335-341

  Costelloe, Lisa ^a   Jones, Joanne ^a   Coles, Alastair ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

alemtuzumab; autoimmunity; IL 21; immune thrombocytopenic purpura; ITP; lymphopenia; multiple sclerosis; thyroid

Indexed keywords

ALEMTUZUMAB; ANTIRETROVIRUS AGENT; BETA1A INTERFERON; CARBIMAZOLE; INTERLEUKIN 21; LEMTRADA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BRAIN HEMORRHAGE; CD4+ T LYMPHOCYTE; DRUG DOSE COMPARISON; GOODPASTURE SYNDROME; GRAVES DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK FACTOR; SECONDARY AUTOIMMUNE DISEASE; T LYMPHOCYTE; THROMBOCYTOPENIA; THYROID DISEASE; THYROIDITIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; HUMANS; INTERLEUKINS; LYMPHOPENIA; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS;

EID: 84863396793     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.5     Document Type: Review

References (30)

1. The International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476, 214-219 (2011).
2. Coles AJ, Cox A, LePage E et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253, 98-108 (2006). (Pubitemid 43157395)
3. CAMMS 223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
4. Coles AJ, Fox E, Vladic A et al. Alemtuzumab treatment of multiple sclerosis: five-year follow-up of the CAMMS223 trial. Neurology (2012) (In Press).
5. Jones JL, Anderson JM, Phuah C-L. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133, 2232-2247 (2010).
6. Coles AJ, Wing M, Smith S et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354, 1691-1695 (1999). (Pubitemid 29533060)
7. De Keyser J. Autoimmunity in multiple sclerosis. Neurology 38, 371-374 (1988). (Pubitemid 18083669)
8. Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon-beta 1b. Arch. Neurol. 54, 1169-1170 (1997). (Pubitemid 27396486)
9. Cossburn M, Pace AA, Jones J et al. Autoimmune diseases after alemtuzumab treatment for multiple sclerosis in a multicentre cohort. Neurology 77, 573-579 (2011).
10. Coles AJ, Brinar V, Arnold DL et al.; the CARE-MS I investigators. Efficacy and safety results from CARE-MS I: a Phase 3 study comparing alemtuzumab and interferon Beta-1a Presented at: ECTRIMS 2011: 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands, 19-22 October 2011.
11. Niederwieser G, Buchinger W, Bonelli RM et al. Prevalance of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J. Neurol. 250, 672-675 (2003). (Pubitemid 36718353)
12. Hale G, Rebello P, Brettman LR et al. Blood concentration of alemtuzumab and anti-globulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104, 948-955 (2004). (Pubitemid 39043667)
13. Hill-Cawthorne GA, Button T, Tuohy O et al. Long-term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J. Neurol. Neurosurg Psychiatry doi:10.1136/ jnnp-2011-300826 (2011) (Epub ahead of print).
14. Thompson SAJ, Jones JL, Cox AL et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J. Clin. Immunol. 30, 99-105 (2010).
15. Cox AL, Thompson SAJ, Jones JL et al. Lymphocyte homeostasis following lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 35, 3332-3342 (2005). (Pubitemid 41672537)
16. Hakim FT, Memon SA, Cepeda R et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J. Clin. Invest. 115(4), 930-939 (2005). (Pubitemid 40489397)
17. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192(4), 549-556 (2000). (Pubitemid 30666255)
18. Goldrath AW, Bogatski LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis driven proliferation. J. Exp. Med. 192, 557-564 (2000). (Pubitemid 30666256)
19. Murali-Krishna K, Ahmed R. Cutting edge: naive T cells masquerading as memory cells. J. Immunol. 165, 1733-1737 (2000). (Pubitemid 30643121)
20. Baccala R, Thiofilopoulos AN. The new paradigm of T cell homeostatic proliferation-induced autoimmunity. Trends Immunol. 26, 5-8 (2005). (Pubitemid 40051984)
21. Loh Y, Oyama Y, Statkute L et al. Development of a secondary autoimmune disorder after haematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 109, 2643-2648 (2007). (Pubitemid 46425915)
22. Ting SS, Zeigler JB, Vowels MR. Acquired autoimmune thrombocytopenia post bone marrow transplant for severe combined immunodeficiency. Bone Marrow Transplant. 21, 841-843 (1998). (Pubitemid 28190633)
23. DeSimone PR, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initialtion of highly active anti-retroviral therapy. Ann. Intern. Med. 133, 447-454 (2000).
24. Chen F, Day SL, Metcalfe RA et al. Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine 84, 98-106 (2005). (Pubitemid 40418638)
25. Krupica T, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clin. Immunol. 120, 121-128 (2006). (Pubitemid 44088681)
26. Alderuccio F, Toh BH, Tan SS et al. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J. Exp. Med. 178, 419-426 (1993). (Pubitemid 23218190)
27. McHugh RS, Shevach EM. Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ specific autoimmune disease. J. Immunol. 168, 5979-5983 (2002). (Pubitemid 34620008)
28. Powrie F, Leach MW, Mauze S et al. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 5, 1461-1471 (1993). (Pubitemid 23325202)
29. King C, Ilic A, Koelsch K et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 117, 265-277 (2004). (Pubitemid 38496245)
30. Jones JL, Phuah C-L, Cox AL et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J. Clin. Invest. 119, 2052-2061 (2009).